NASDAQ:BLUEbluebird bio Stock Price, Forecast & News

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BLUE stock has increased by 15.6% and is now trading at $71.12. View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for bluebird bio.

bluebird bio is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for bluebird bio.

bluebird bio Inc (NASDAQ:BLUE) posted its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($3.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.05) by $0.41. The biotechnology company earned $21.90 million during the quarter, compared to analyst estimates of $8 million. bluebird bio had a negative net margin of 1,531.04% and a negative return on equity of 60.05%. The business's revenue was up 75.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.99) EPS. View bluebird bio's earnings history.

20 Wall Street analysts have issued 12 month target prices for bluebird bio's shares. Their forecasts range from $70.00 to $195.00. On average, they anticipate bluebird bio's stock price to reach $115.47 in the next twelve months. This suggests a possible upside of 62.4% from the stock's current price. View analysts' price targets for bluebird bio.

Media headlines about BLUE stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. bluebird bio earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutbluebird bio.

Some companies that are related to bluebird bio include BioNTech (BNTX), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), argenx (ARGX), Repligen (RGEN), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF) and Momenta Pharmaceuticals (MNTA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Celgene (CELG), Incyte (INCY), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU) and Medivation (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (12.26%), Capital Research Global Investors (12.24%), Capital World Investors (7.80%), Sands Capital Management LLC (5.61%), BlackRock Inc. (5.18%) and Victory Capital Management Inc. (3.10%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory, Susanna Gatti High and William D Baird III. View institutional ownership trends for bluebird bio.

BLUE stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Wellington Management Group LLP, Capital International Investors, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Nikko Asset Management Americas Inc., Victory Capital Management Inc., and Victory Capital Management Inc.. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, and William D Baird III. View insider buying and selling activity for bluebird bio.

BLUE stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, TimesSquare Capital Management LLC, Casdin Capital LLC, Two Sigma Investments LP, Fiera Capital Corp, Tarsadia Capital LLC, and Deutsche Bank AG. View insider buying and selling activity for bluebird bio.

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLUE stock can currently be purchased for approximately $71.12.

bluebird bio has a market capitalization of $3.96 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-789,610,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis. bluebird bio employs 1,090 workers across the globe.

The official website for bluebird bio is www.bluebirdbio.com.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]